Arcus Biosciences (RCUS) had its price target raised by Wedbush from $37.00 to $41.00. They now have an "outperform" rating on the stock.
Arcus Biosciences (RCUS) was upgraded by Truist Financial Corporation to "strong-buy".
Arcus Biosciences Announces New Employment Inducement Grants
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors [Yahoo! Finance]
Arcus Biosciences Announces New Employment Inducement Grants